1995
DOI: 10.1016/0006-8993(95)00027-n
|View full text |Cite
|
Sign up to set email alerts
|

Phase-dependent phase shift of methamphetamine-induced circadian rhythm by haloperidol in SCN-lesioned rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
14
0

Year Published

1996
1996
2021
2021

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(14 citation statements)
references
References 16 publications
0
14
0
Order By: Relevance
“…These 5-HT enhancing effects of TSD and LT could also explain the sleep reduction in responders, a phenomenon observed in the present study, because pharmacogenetic studies have showed that human homozygotes for the long variants of the serotonin promoter gene polymorphism, which respond better to both antidepressant TSD and serotonergic drugs (Benedetti et al, 1999), also reduce their sleep and increase their nighttime locomotor activity when treated with SSRIs (Putzhammer et al, 2005). Moreover, the DA-enhancing effects of TSD could contribute to the observed effects, because DA can entrain the activity-rest rhythm (Fertl et al, 1993;Honma & Honma, 1995), regulate the generation of sleep-wake states (Dzirasa et al, 2007), and exert complex effects on the physiological functions of sleep and dream mentation (Dahan et al, 2006). Other neurobiological mechanisms could involve the arousal-enhancing transmitter norepinephrine, which is markedly enhanced by TSD (Conti et al, 2007), or the expression of several immediate-early genes and transcription factors, genes related to energy metabolism, growth factors, adhesion molecules, chaperones, and heat shock proteins, vesicle-and synapserelated genes, neurotransmitter and hormone receptors, neurotransmitter transporters, and enzymes, which are enhanced by TSD (Cirelli & Tononi, 2000).…”
Section: Discussionmentioning
confidence: 65%
“…These 5-HT enhancing effects of TSD and LT could also explain the sleep reduction in responders, a phenomenon observed in the present study, because pharmacogenetic studies have showed that human homozygotes for the long variants of the serotonin promoter gene polymorphism, which respond better to both antidepressant TSD and serotonergic drugs (Benedetti et al, 1999), also reduce their sleep and increase their nighttime locomotor activity when treated with SSRIs (Putzhammer et al, 2005). Moreover, the DA-enhancing effects of TSD could contribute to the observed effects, because DA can entrain the activity-rest rhythm (Fertl et al, 1993;Honma & Honma, 1995), regulate the generation of sleep-wake states (Dzirasa et al, 2007), and exert complex effects on the physiological functions of sleep and dream mentation (Dahan et al, 2006). Other neurobiological mechanisms could involve the arousal-enhancing transmitter norepinephrine, which is markedly enhanced by TSD (Conti et al, 2007), or the expression of several immediate-early genes and transcription factors, genes related to energy metabolism, growth factors, adhesion molecules, chaperones, and heat shock proteins, vesicle-and synapserelated genes, neurotransmitter and hormone receptors, neurotransmitter transporters, and enzymes, which are enhanced by TSD (Cirelli & Tononi, 2000).…”
Section: Discussionmentioning
confidence: 65%
“…We demonstrated in previous studies that MAP coadministered with the D 1 /D 2 receptor antagonist, haloperidol, the D 1 receptor antagonist, SCH23390, or the NMDA receptor antagonist, MK‐801, inhibited the development of MAP‐induced anticipatory locomotor activity and mPer1 gene expression in the striatum (Shibata et al ., 1995; Nikaido et al ., 2001). In addition, Honma & Honma (1995) reported that the free‐running rhythm induced by ingested MAP was reset by haloperidol. Taken together, these results suggest that both D 1 and NMDA receptor subtypes are involved in the appearance of MAP‐associated behavioural rhythms and mPer gene expression.…”
Section: Discussionmentioning
confidence: 99%
“…Injections of Haloperidol, which is a dopamine antagonist with some sedative effects, cause phase-shifts of the MAPinduced circadian activity rhythms in SCN-lesioned arrhythmic female rats. In contrast, Pentobarbital or ether, which also has similar sedative effects, do not cause phase-shifts (Honma and Honma 1995). This suggests that the dopaminergic system is either involved in the entraining pathway of MASCO or in MASCO itself.…”
Section: Localization Of Mascomentioning
confidence: 91%
“…Both dopamine and serotonin systems seem to be involved in the circadian effects of MAP (Honma and Honma 1995). Injections of Haloperidol, which is a dopamine antagonist with some sedative effects, cause phase-shifts of the MAPinduced circadian activity rhythms in SCN-lesioned arrhythmic female rats.…”
Section: Localization Of Mascomentioning
confidence: 99%
See 1 more Smart Citation